NLM Digital Collections

Search

Start Over Formats Text ✖Remove constraint Formats: Text Copyright Public domain ✖Remove constraint Copyright: Public domain Recently Added Within 6 Months ✖Remove constraint Recently Added: Within 6 Months Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

41. Competition in prescription drug markets, 2017-2022

Author(s):
Parasrampuria, Sonal, author
Murphy, Stephen J. (Stephen James), author
Publication:
Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services, December 2023
Subject(s):
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Economic Competition
Drug Industry -- economics
Drug Industry -- trends
Prescription Drugs -- economics
United States

42. Compliance policy regarding blood and blood component donation suitability, donor eligibility and source plasma quarantine hold requirements: guidance for industry

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, October 2023
Subject(s):
Blood Banking -- standards
Blood Donation -- standards
Blood Donors
Donor Selection -- standards
Government Regulation
Guideline Adherence
Plasma
United States

45. Connecticut implemented our prior audit recommendations and generally complied with federal and state requirements for reporting and monitoring critical incidents

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2023
Subject(s):
Government Regulation
Group Homes -- standards
Guideline Adherence -- legislation & jurisprudence
Mandatory Reporting
Medical Errors -- legislation & jurisprudence
Connecticut

47. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, August 2023
Subject(s):
Biological Products
Clinical Trials as Topic
Data Analysis
Decision Making
Drug Approval
Drug Industry
Drug and Narcotic Control
Government Regulation
United States
United States.

48. The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2023
Subject(s):
Government Regulation
Medicare
Opiate Overdose -- prevention & control
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States